RGP Earnings

RGP reported its earnings on 2026-01-07, showcasing a revenue of 118.00M against an estimate of 120.00M, resulting in a -1.91% surprise. The EPS was 0.01, surpassing the expected -0.08 by 112.5% . The stock experienced a -14.61% price change on the earnings day and a -11.95% change over the next five days, reflecting market reactions to the results.

Following RGP's earnings announcement on 2026-01-07, the stock price moved by -14.61% on the day of the release. Over the subsequent five days, it saw a -11.95% change. Historically, RGP's stock price tends to shift by an average of +2.96% in the 10 days leading up to earnings and -8.50% in the 10 days following, providing insight into potential market.

For 2026/Q3, analysts estimate RGP’s annual revenue to reach 108.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between RGP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RGP's stock price typically moves by +2.96% in the 10 days before its earnings and -8.50% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 0.00 and revenue of 108.00M.

The earnings call highlighted declines in key segments, with significant year-over-year revenue drops in both On-Demand and Consulting segments. Despite some growth in Outsourced Services, the overall financial performance was weak. The Q&A section further revealed concerns about AI's impact on roles and unclear management responses on strategic vision. Additionally, healthcare costs impacted margins, and while SG&A expenses improved, the lack of strong positive catalysts and weak guidance suggest a negative stock price reaction in the near term.